Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Sinovation / 华科精准

Explore full profile

Focuses on developing medical robot technology and intelligent medical product innovation

ChinaFounded 2015Health Tech & Medtech
Valuation $100–250M Last recorded · 2023
Headcount <100 Current team size
Total funding $50–100M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Sinovation / 华科精准 and the history behind them.

About Sinovation / 华科精准

Sinovation Medical Technology Co., Ltd., established in August 2015, is a medical technology firm focused on developing and manufacturing intelligent medical devices for neurosurgery. The company provides comprehensive technology and product solutions for treating brain diseases like epilepsy, Parkinson's disease, brain tumors, and cerebral hemorrhage. Its technology originates from two decades of research at Tsinghua University.

Read full description

The company was co-founded by Wang Ke, Wu Di, and Dr. Liu Wenbo. Wang Ke, a graduate of Peking University's Health Science Center, has extensive clinical and business experience. Wu Di, an alumnus of Xi'an Jiaotong University Health Science Center, previously worked at Capital Medical University Xuanwu Hospital. Dr. Liu Wenbo holds a Ph.D. from Tsinghua University's School of Medicine and has deep expertise in neurosurgical navigation systems. Their journey began in 2005 when Wu Di and Wang Ke founded Beijing Huake Hengsheng Medical Technology to develop and produce medical electrodes for neurosurgery. Recognizing the limitations in the market, they decided to develop surgical robots, initiating research and development with Tsinghua University in 2011, which led to the formation of Sinovation Medical.

Sinovation Medical operates on a business model that combines the sale of high-end medical equipment with associated high-value consumables and technical services. Its clients are primarily hospitals and medical institutions, with its products used in over 250 hospitals across China. The firm has established a significant market presence, with its intracranial electrodes and neurosurgical robots holding a leading share in the domestic market. The business has expanded globally, notably after receiving FDA approval for its Sinobot X1, paving the way for international sales.

The company's product portfolio is organized into six main lines: the SR series of neurosurgical robots, the Q300 series of miniature neurosurgical robots, the NS series of neurosurgical navigation systems, the X1000 series for brain and spinal surgery, the LS series of MRI-guided laser ablation therapy systems, and a comprehensive range of intracranial electrodes through its subsidiary, Huake Hengsheng. A key product, the Sinobot X1, is the first neurosurgical robot from a Chinese company to receive FDA clearance in the United States. Another significant offering is the Laser Interstitial Thermal Therapy (LITT) system, the first domestically developed system of its kind in China for treating brain tumors and epilepsy. The company's robots integrate advanced features like 3D structured light for markerless registration, enhancing surgical precision and efficiency.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2015
Headquarters
China
Employees
23
Open positions
None listed
Dealroom signal
47.7/100
Industry
Health, Robotics
Sub-industry
Health Platform
Sector
Health Tech & Medtech, Surgery, Core AI, Medical Robots, Surgical Equipment, Collaborative Robots, Surgical Robots, Hard Tech, AI Applications, DT and LS, science-based
Business model
Manufacturing

Funding history

5 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES DOther financing Jul 2023 $14M $206M Rongquan Capital · Mizuki Investment · Huiyu Investment · DNV capital ↗
SERIES DOther financing Dec 2022 $41M $165M Green River Delta · Denuo Capital Group · Kaifeng Venture Capital · Rongquan Capital ↗
Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Sinovation / 华科精准 website traffic

Latest recorded traffic for Sinovation / 华科精准 is 1.3K monthly website visits, down 27.8% over the last three months. Sinovation / 华科精准's team grew 4.5% over the past year.

Latest monthly visits1.3K 3-month web change-27.8% 1-year team growth+4.5%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Investors

12 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

  • Cowin Venture
  • Pins Medical

Series B and later9 investors entered at this stage

  • Green River Delta
  • Denuo Capital Group
  • Kaifeng Venture Capital
  • Rongquan Capital
  • Mizuki Investment
  • Huiyu Investment
  • DNV capital
  • Cinda Kunpeng
  • Junshan Private Equity

Other known investors1 additional known investor

  • NLVC
Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
3 countries with
team presence
🇨🇳 China77.8%
🇳🇿 New Zealand11.1%
🇭🇰 Hong Kong11.1%
3 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Sinovation / 华科精准 on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Sinovation / 华科精准’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.